1-4 of 4
Adam D. Kennedy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PI3K and NADPH oxidase: a class act

Adam D. Kennedy, Frank R. DeLeo
Journal: Blood
Blood (2008) 112 (13): 4788–4789.
https://doi.org/10.1182/blood-2008-09-179135
Published: 2008
Journal Articles

Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.

Michael E. Williams, MD, John J. Densmore, MD, PhD, Andrew W. Pawluczkowycz, MS, Paul V. Beum, PhD, Adam D. Kennedy, PhD, Margaret A. Lindorfer, PhD, Susan H. Hamil, RN, Gina R. Petroni, PhD, Jane C. Eggleton, RN, Ronald P. Taylor, PhD
Journal: Blood
Blood (2005) 106 (11): 2970.
https://doi.org/10.1182/blood.V106.11.2970.2970
Published: 2005
Journal Articles

A Pilot Study of Thrice-Weekly Low Dose Rituximab (RTX) in the Treatment of Chronic Lymphocytic Leukemia (CLL) Suggests Enhanced Therapeutic Targeting Compared to Standard Dose Regimens.

Ronald P. Taylor, Ph.D., Andrew W. Pawluczkowycz, M.S., Paul V. Beum, Ph.D., Adam D. Kennedy, M.S., Margaret A. Lindorfer, Ph.D., John J. Densmore, M.D., Ph.D., Jane Eggleton, R.N., Karen L. LoRusso, M.D., Michael E. Williams, M.D.
Journal: Blood
Blood (2004) 104 (11): 2520.
https://doi.org/10.1182/blood.V104.11.2520.2520
Published: 2004
Journal Articles

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20 + cells by rituximab

Adam D. Kennedy, Michael D. Solga, Theodore A. Schuman, Amos W. Chi, Margaret A. Lindorfer, William M. Sutherland, Patricia L. Foley, Ronald P. Taylor
Journal: Blood
Blood (2003) 101 (3): 1071–1079.
https://doi.org/10.1182/blood-2002-03-0876
Published: 2003